Stock Market Today, Dec. 16: Pfizer Falls After Cutting 2025 Revenue Forecast

Pfizer shares fell 3.41% to $25.53 on heavy volume after the company trimmed 2025 revenue expectations to roughly $62 billion (from a prior range near $61–64 billion) and warned of faster-than-expected COVID-19 revenue erosion; it reaffirmed 2025 adjusted EPS of $3.00–$3.15 and forecast flat 2026 revenues of $59.5–$62.5 billion. Management said it will cut costs and redeploy savings into R&D, highlighted a recent acquisition in obesity and cardiometabolic medicines and plans to advance obesity trials in 2026, but cautioned that new initiatives could take time to restore growth. The guidance ripple hit large-cap pharma peers (Merck and J&J fell about 2%), leaving investors focused on the timing and scale of product and deal-driven recovery for earnings.

Analysis

Pfizer shares fell 3.41% to $25.53 on Dec. 16 on unusually heavy trading of 108.1 million shares, roughly 60% above the three‑month average, after management trimmed top‑line expectations and flagged faster COVID‑19 revenue erosion. The move weighed on large‑cap peers—Merck and Johnson & Johnson declined about 1.99% and 2.27%, respectively—while the S&P500 slipped 0.26% and the Nasdaq rose 0.23%, indicating sector‑specific reassessment rather than broad market stress.

Management reduced 2025 revenue guidance to about $62.0 billion (from a prior $61–$64 billion range) while reaffirming 2025 adjusted EPS of $3.00–$3.15 and forecasting flat 2026 revenues of $59.5–$62.5 billion, citing COVID drug declines and expiring patents as the primary drivers. The EPS reaffirmation suggests near‑term margin management or buybacks are stabilizing earnings per share even as top‑line pressure persists.

Pfizer is responding with cost cuts and redeploying savings into R&D, including a recent acquisition in obesity/cardiometabolic medicines and plans to advance obesity trials in 2026; management cautioned these initiatives could take time to offset lost COVID revenue. Key implications are elevated near‑term top‑line risk, potential volatility around trial and M&A milestones, and a medium‑term reliance on successful product launches to restore growth.

Key Decisions for Investors

• Avoid initiating large new long positions in PFE until revenue trend or product‑driven catalysts provide clearer evidence of stabilization or upside
• Monitor three discrete catalysts as buy/sell triggers: quarterly revenue cadence for COVID portfolio erosion, 2026 guidance updates, and progress/readouts from obesity trials and related M&A integration
• Consider short‑dated hedges (puts or collars) or reducing exposure to limit downside given elevated volume and heightened sell‑side reassessment of pharma earnings
• Reassess broader large‑cap pharma allocations (MRK, JNJ) if guidance‑led weakness persists, using Pfizer’s upcoming disclosures as a barometer for sector earnings durability